Skip to main content
. 2020 Sep 1;28(10):1276–1289. doi: 10.1016/j.jsps.2020.08.018

Table 1.

Effects of sesamin on hypertension.

Reference Experimental Model Dosage Administration Mode Administration Duration Experimental N Response
Animal Models
Kita et al. (1995) Sprague-Dawley rats with two-kidney, one-clip hypertension 1 w/w%
(10 g/kg)
Oral 4 weeks 11 Suppression of kidney clip-induced increase in systolic BP (42 mmHg decrease)
Matsumura et al. (1995) Sprague-Dawley rats with DOCA salt-induced hypertension 1 w/w%
(10 g/kg)
Oral 5 weeks 8 Suppression of DOCA salt-induced increase in systolic BP (46 mmHg decrease)
Matsumura et al. (1998) Stroke-prone spontaneously hypertensive rats 1 w/w%
(10 g/kg)
Oral 24 weeks 7–9 Suppression of systolic BP increase, 15–30 mmHg decrease in systolic BP
Matsumura et al. (2000) Sprague-Dawley rats with DOCA salt-induced hypertension 1 w/w%
(10 g/kg)
Oral 5 weeks 8 Suppression of DOCA salt-induced increase in systolic BP (28 mmHg decrease)
Noguchi et al. (2001) Stroke-prone spontaneously hypertensive rats 1000 mg/kg Oral 5 weeks 3 Decrease in systolic BP by sesamin treatment (20 mmHg decrease), vitamin E treatment (31 mmHg decrease), and sesamin + vitamin E treatment (52 mmHg decrease)
Nakano et al. (2003) Sprague-Dawley rats with DOCA salt-induced hypertension 0.1 w/w% (1 g/kg),
1 w/w%
(10 g/kg)
Oral 5 weeks 14 Dose-dependent decrease in systolic BP (0.1 w/w% diet − 29.2 mmHg decrease, 1 w/w% diet − 46 mmHg decrease)
Nakano et al. (2008) Sprague-Dawley rats with DOCA salt-induced hypertension 1 w/w%
(10 g/kg)
Oral 5 weeks 6 Suppression of DOCA salt-induced increase in systolic BP (36.8 mmHg decrease), NADPH activity, and mRNA expression of p22phox, gp91phox, and Nox1
Kong et al. (2009) Sprague-Dawley rats with two-kidney, one-clip hypertension 60, 120 mg/kg Oral 8 weeks 7 Decrease in systolic BP by 11% (60 mg treatment) and 17% (120 mg treatment)
Li et al. (2015) Sprague-Dawley rats with monocrotaline-induced pulmonary hypertension 50, 100 mg/kg Oral 4 weeks 12 Decrease in right systolic ventricular pressure and mean arterial pressure
Kong et al. (2015a) Spontaneously hypertensive rats 80, 160 mg/kg Oral 8 weeks 10 Decrease in systolic BP by 12% (80 mg treatment) and 16% (160 mg treatment)
Thuy et al. (2017) Sprague-Dawley rats with STZ-induced type 1 diabetes 50, 100, 200 mg/kg Oral 4 weeks 5 Increase in systolic BP and diastolic BP in STZ-induced rats (50 mg, 17/8.2 mmHg increase, 100 mg, 37.8/14.7 mmHg increase, 200 mg, 38.6/17.5 mmHg increase)
Human Subjects
Miyawaki et al. (2009) Japanese, middle-aged, mildly hypertensive patients 10 mg/capsule.
3 capsules twice per day
Oral 4 weeks 12–13 Decrease in systolic BP by 3.5 mmHg and diastolic BP by 1.9 mmHg
Helli et al. (2016) Iranian, overweight (BMI 25–35), middle-aged, RA patients 200 mg per day Oral 6 weeks 22 Decrease in systolic BP by 4.3 mmHg and diastolic BP by 1.0 mmHg